Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited

Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society
Ahmad Al-SaffarPer M Hellström

Abstract

Metoclopramide is primarily a dopamine receptor antagonist, with 5HT3 receptor antagonist and 5HT4 receptor agonist activity, and used as an antiemetic and gastroprokinetic since almost 50 years. Regulatory authorities issued restrictions and recommendations regarding long-term use of the drug at oral doses exceeding 10 mg 3-4 times daily because of the risk for development of tardive dyskinesia. The aim of our study was to review mechanism(s) of action and pharmacokinetic-pharmacodynamic properties of metoclopramide, as well as the risk of metoclopramide-induced tardive dyskinesia, factors that may change drug exposure in humans, and to summarize the clinical context for appropriate use of the drug. A PubMed, Google Scholar, and Cross Reference search was done using the key words and combined searches: drug-drug interaction, gastroparesis, metoclopramide, natural history, pharmacokinetics, pharmacodynamics, drug-drug interaction, outcome, risk factors, tardive dyskinesia. Data show that the risk of tardive dyskinesia from metoclopramide is low, in the range of 0.1% per 1000 patient years. This is far below a previously estimated 1%-10% risk suggested in treatment guidelines by regulatory authorities. High-risk groups are elder...Continue Reading

References

Nov 1, 1979·British Journal of Clinical Pharmacology·C GraffnerO Rönn
Nov 1, 1992·Archives of Family Medicine·D D Sewell, D V Jeste
Jan 1, 1992·Schizophrenia Bulletin·R Yassa, D V Jeste
Jan 1, 1991·European Archives of Psychiatry and Clinical Neuroscience·T InadaY Masuda
Feb 1, 1991·British Journal of Clinical Pharmacology·E MagueurA M Taburet
Apr 1, 1989·European Journal of Pediatrics·P DemolT R Weihrauch
May 1, 1986·Acta Psychiatrica Scandinavica·R Yassa, S Lal
Oct 1, 1988·British Journal of Clinical Pharmacology·M R WrightJ D Price
Oct 5, 1985·British Medical Journal·D N BatemanJ M Simpson
Mar 1, 1986·British Journal of Clinical Pharmacology·D WebbP A Routledge
Apr 1, 1982·Archives of General Psychiatry·J M Kane, J M Smith
Jan 1, 1983·Annals of Internal Medicine·R Albibi, R W McCallum
Feb 18, 1984·British Medical Journal·B E WiholmJ E Häggström
Jan 1, 1981·European Journal of Clinical Pharmacology·D N BatemanP G Blain
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Nov 1, 1994·Biological Psychiatry·D D SewellD V Jeste
Jan 1, 1993·Acta Psychiatrica Scandinavica·G MuscettolaP Bollini
Jun 1, 1993·The American Journal of Psychiatry·M G WoernerJ M Alvir
Jul 14, 2000·The American Journal of Gastroenterology·G TougasR W McCallum
Oct 29, 2000·Trends in Neurosciences·C R Gerfen
Feb 21, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zeruesenay DestaD A Flockhart
Mar 26, 2004·The Pharmacogenomics Journal·D J MüllerJ L Kennedy
Nov 3, 2004·Gastroenterology·Henry P ParkmanUNKNOWN American Gastroenterological Association
Jan 11, 2005·Journal of the American Pharmacists Association : JAPhA·Douglas ShafferAnn Corken Mackey
Apr 19, 2005·Molecular Pharmaceutics·Nehal A KasimGordon L Amidon
Mar 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·P Jay PasrichaJoseph Jankovic
Mar 24, 2006·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·T L AbellA I Vinik
May 20, 2006·Bulletin of the World Health Organization·Xavier Seuba
May 10, 2007·The American Journal of Gastroenterology·Savio C ReddymasuRichard W McCallum
Jun 19, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Pascale JollietRoméo Cecchelli
Jan 29, 2008·Journal of Clinical Pharmacology·Christopher KenneyJoseph Jankovic
Feb 14, 2008·Journal of Pharmaceutical Sciences·A G StosikD M Barends
Nov 6, 2009·Alimentary Pharmacology & Therapeutics·A S Rao, M Camilleri
Dec 7, 2010·Postgraduate Medical Journal·Roongroj Bhidayasiri, Suthida Boonyawairoj
Feb 10, 2011·Pharmacological Reviews·Jean-Martin Beaulieu, Raul R Gainetdinov
Jun 13, 2012·Journal of Clinical Gastroenterology·Henry P ParkmanEvgeny Krynetskiy
Sep 12, 2012·Pharmaceutical Development and Technology·Randa Latif

❮ Previous
Next ❯

Citations

Dec 4, 2019·Current Diabetes Reports·Ryan JallehMichael Horowitz
Jul 22, 2020·Drugs·Gregory S Sayuk, C Prakash Gyawali
Sep 24, 2020·Clinical Pharmacology and Therapeutics·Martin BauerOliver Langer
Oct 9, 2019·Best Practice & Research. Clinical Gastroenterology·Serhat Bor
Mar 20, 2021·Expert Review of Endocrinology & Metabolism·Mahesh GajendranRichard McCallum
May 12, 2021·Journal of Pain & Palliative Care Pharmacotherapy·Elizabeth M GavioliEtty Vider

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Epigenetics Insights from Twin Studies

Find the latest research on epigenetics and twin studies here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Related Papers

Biological Psychiatry
D D SewellD V Jeste
Alimentary Pharmacology & Therapeutics
A S Rao, M Camilleri
The New England Journal of Medicine
J C Mahler, R P Brown
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
L Beuclair, R Fontaine
© 2021 Meta ULC. All rights reserved